Medios AG is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, as part of an optimization of its Germany-wide manufacturing network. The company is consolidating patient-specific manufacturing at its remaining locations, with production already relocated and supplies to pharmacies and hospitals guaranteed. Aschaffenburg accounted for approximately 10% of the production volume of the Medios Group’s German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation.
The business of patient-specific formulations is under sustained margin pressure, particularly due to price regulatory adjustments. Medios is countering these challenges with measures to increase efficiency under its Operational Excellence Program. In Germany, Medios operates a network of six GMP manufacturing facilities for patient-specific therapies (GMP stands for “Good Manufacturing Practice,” which entails mandatory production standards and validated quality management). The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization, making continued economic operation no longer feasible. Structural renovation work required at the site accelerated the decision to close.
Thomas Meier, CEO of Medios AG, stated: “With a view to ensuring a reliable supply for our customers and maintaining capacity utilization at all sites, we are now optimizing our successful regional presence strategy and consistently developing it further. With Mannheim and Stuttgart, we have two high-performing Medios sites in southern Germany, ensuring that a reliable supply is maintained.”
The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability. Medios AG is a leading provider of Specialty Pharma in Europe, with locations in Germany, the Netherlands, Belgium, and Spain. The company supports key partners in the supply chain with innovative solutions and intelligent services, focusing on pioneering individualized medicine.
Important events for the Medios Group in the 2026 financial year include the half-year financial report on August 12, the Berenberg and Goldman Sachs 15th German Corporate Conference in Munich from September 21 to 23, the Medios Capital Markets Day in Breda on September 28/29, and the quarterly statement as of September 30, 2026 on November 10.
This announcement underscores the challenges facing the specialty pharmaceutical sector due to regulatory pressures and the need for operational efficiency. Medios’ decision to consolidate manufacturing is a strategic move to maintain competitiveness and ensure long-term sustainability. The company’s shares are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.
